がん研セミナー(12月9日)のお知らせ

演題：Revolutionizing the discovery processes of therapeutically worthy peptides

演者：菅　裕明 博士（東京大学大学院理学系研究科化学専攻生物有機化学研究室・教授）

抄録：Macrocyclic peptides possess a number of pharmacological characteristics distinct from other well-established therapeutic molecular classes, resulting in a versatile drug modality with a unique profile of advantages. Macrocyclic peptides are accessible by not only chemical synthesis but also ribosomal synthesis. Particularly, recent inventions of the genetic code reprogramming integrated with an in vitro display format, referred to as RaPID (Random non-standard Peptides Integrated Discovery) system, have enabled us to screen mass libraries (>1 trillion members) of non-standard peptides containing multiple non-proteinogenic amino acids, giving unique properties of peptides distinct from conventional peptides, e.g. greater proteolytic stability, higher affinity (low nM to sub nM dissociation constants similar to antibodies), and superior pharmacokinetics. The field is rapidly growing evidenced by increasing interests from industrial sectors, including small start-ups as well as mega-pharmas, toward drug development efforts on macrocyclic peptides, which has led to several de novo discovered peptides entering clinical trials. 

This lecture discusses the aforementioned screening technology, the RaPID system, and several showcases of therapeutic potentials of macrocyclic peptides. This lecture also discusses an application of the RaPID peptides to biologics development.

日時：２０１９年１２月９日（月） １５：００〜１６：００

場所：吉田記念講堂

連絡先：旦 慎吾（内線５４３２）

＊外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。